Clinical Trials Logo

Clinical Trial Summary

A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effect of recombinant human Neuregulin-1 for injection on cardiac function and reverse ventricular remodeling in male patients with NT-proBNP ≤ 1700 pg/ml and female patients with NT-proBNP ≤ 4000 pg/ml and New York Heart Association class II-III chronic systolic heart failure, and to confirm its efficacy and safety.


Clinical Trial Description

This trial is planned to be conducted simultaneously in multiple clinical study sites nationwide, including 198 subjects, 99 subjects in the treatment group and 99 subjects in the placebo group. Primary endpoint: 1.Response rate at 35 days of simultaneous reduction of LVESVI and LVEDVI by more than or equal to 20 ml/m2 (The proportion of the subjects achieving this criterion in each treatment group.) Secondary endpoints: 1. Response rate at 35 day of LVESVI improvement greater than or equal to 25 ml/m2 ; 2. Response rate at 35 day of LVEDVI improvement greater than or equal to 25 ml/m2 ; 3. Change from baseline in LVEF, LVESV, LVEDV, LVESVI and LVEDVI at 35 days ; 4. 90-day response rate of LVESVI improved greater than or equal to 25ml/m2,LVEDVI improved greater than or equal to 25 ml/m2, and LVESVI and LVEDVI improved greater than or equal to 20 ml/m2 at the same time ; 5. Change from baseline in LVEF, LVESV, LVEDV, LVESVI and LVEDVI at 90 days ; 6. Change from baseline in NYHA at 35 and 90 days ; 7. Change from baseline in quality of life at 35 and 90 days ; 8. Mortality during the study period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05949801
Study type Interventional
Source Zensun Sci. & Tech. Co., Ltd.
Contact Xiaoyan Qin, ph.D
Phone 86-021-50802627
Email qinxiaoyan@zensun.com
Status Recruiting
Phase Phase 3
Start date April 13, 2023
Completion date August 2024

See also
  Status Clinical Trial Phase
Suspended NCT04589065 - SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device) N/A
Completed NCT02248441 - Effect of Remote Ischemic Conditioning in Patients With Chronic Ischemic Heart Failure N/A
Recruiting NCT02188082 - Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets (FIRST) Phase 2/Phase 3
Terminated NCT01439893 - Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients Phase 3
Recruiting NCT03504891 - Cardiac MRI for Optimal Heart Failure Outcomes With CRT Upgrades Phase 1
Active, not recruiting NCT04468529 - Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure Phase 3
Active, not recruiting NCT01639378 - Renal Artery Denervation in Chronic Heart Failure Study Phase 3
Completed NCT02809131 - Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. Phase 3